Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002
HER-2/neu oncoprotein expression in nonsmall cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002
The expression of Ki-67, a marker of proliferative activity, in resected nonsmall cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 478s Year: 2001
Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer Source: Eur Respir J 2001; 17: 660-666 Year: 2001
The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003
Ki-67 in non-small cell lung cancer Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012
Survivin expression in non-small cell lung cancer Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010
p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001
The association of p53 and p21 expression with clinicopathological parameters and prognosis in non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010
Prognostic value of p21 protein expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004
Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001
FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC). Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021
An analysis of EGFR expression and tumour imaging in non-small cell carcinomas of lung Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011
Management of EGFR mutated nonsmall cell lung carcinoma patients Source: Eur Respir J 2015; 45: 1132-1141 Year: 2015
Immunohistochemical studies of COX-2, MMP-9, p53 and VEGF in non-small-cell lung cancer, specifically squamous cell carcinoma and adenocarcinoma Source: Eur Respir J 2006; 28: Suppl. 50, 387s Year: 2006
Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017
Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006
Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001
T790M-mutation in EGFR progressive non-small cell lung cancer, role of re-biopsy and ctDNA analysis Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017
How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015